21 results about "Colonic mucosa" patented technology

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

The invention provides an effective mucous membrane coverage rate-based colonoscope retreating quality real-time evaluation method and system, and relates to the technical field of medical image calculation and processing. The colonoscope retreating quality real-time evaluation method based on the effective mucous membrane coverage rate comprises the steps that a retreating video is obtained, and the retreating video comprises a real-time retreating video and a historical video; preprocessing the mirror retreating video to obtain an optimized data set; extracting effective frames based on the optimized data set; and inputting the effective frame into a preset image segmentation model to obtain an effective colonic mucosa coverage rate which is used for evaluating the despeculation quality. According to the colonoscope retreating quality real-time evaluation method based on the effective mucous membrane coverage rate, the technical problem that the clinical colonoscope retreating process lacks real-time supervision and feedback in the prior art is solved.

The present invention addresses the problem of: developing a method capable of noninvasively sampling and analyzing intestinal mucosa bacteria; analyzing the intestinal bacteria, especially intestinal mucosa bacteria on the basis of the method; and developing a therapeutic method for diseases occurring in the intestinal tract for which therapeutic methods have not been established.　The inventors of the present invention have found that bacteria contained in a cotton swab (swab) sample on the feces surface exhibit a bacterial flora composition similar to that of bacteria existing in the intestinal mucosa; and, as a result of analysis based on the finding, have clarified that Adlercreutzia, which has not been reported until now as a mucosa-related bacterium, lives in the large intestinal mucosa layer, produces taurine, which is a strong anti-inflammatory compound, by the action of the bile acid-deconjugating enzyme, and alleviates enteritis, thereby completing the present invention. In other words, the present invention can provide a composition having an anti-inflammatory effect, which includes a bacterium of the genus Adlercreutzia, or a bile acid-deconjugating enzyme that is derived from a bacterium of the genus Adlercreutzia.

The invention discloses application of a pain and diarrhea prescription to regulation and control of a BLP + macrophage subgroup to treat IBS-D. The pain and diarrhea prescription contains a liver soothing component (6-10 parts of pericarpium citri reticulatae and 6-10 parts of radix saposhnikoviae) and a spleen tonifying component (10-15 parts of rhizoma atractylodis macrocephalae and 10-15 parts of radix paeoniae alba) or a combination of the liver soothing component and the spleen tonifying component according to the ratio of 1: (1-2). By promoting the expression of anti-inflammatory cytokines IL-10 and TGF-beta, inhibiting the expression of pro-inflammatory cytokines IL-6 and TNF-alpha, activating an AMPK signal channel, inhibiting an NF-kappa B signal channel and promoting the expression of colonic mucosal barrier indexes ZO1 and OCLN, a colonic mucosal barrier is repaired, and the symptoms of IBS-D abdominal pain and diarrhea are relieved. The invention also provides a pharmaceutical composition containing the key active component, and the dosage forms comprise an aqueous solution, a tablet and the like. The traditional Chinese medicine composition solves the problems of large toxic and side effects, poor compliance and unknown mechanism in the existing IBS-D treatment, is definite and safe in curative effect, and has important clinical value and scientific significance.

The application discloses application of a reagent for detecting a biomarker in preparation of a product for predicting ulcerative colitis disease activity or a product for diagnosing ulcerative colitis disease, and relates to the technical field of serological markers of inflammatory bowel disease. The serum CD105 of a UC patient is significantly higher than that of a healthy control group, and CD105 has a very high effect of diagnosing ulcerative colitis disease, and CD105 can distinguish disease activity from remission. Therefore, the application provides a novel serum marker which is convenient to sample, has good repeatability and can objectively reflect the colon mucosa inflammation load, and is expected to provide more accurate marker selection for UC disease activity prediction and UC diagnosis.

The invention provides an exosome oral soluble film with a multi-targeting function, which is prepared from the following components in parts by weight: 10 to 20 parts of active substances, 20 to 60 parts of carrier materials for wrapping exosomes or drug-loaded exosomes, 50 to 100 parts of film-forming agents, 20 to 40 parts of disintegrating agents, 10 to 25 parts of plasticizers, 1 to 5 parts of flavoring agents and 1 to 10 parts of antioxidants, wherein the active substance is an exosome or a drug-loaded exosome, and the carrier material is a polylactic acid-glycolic acid copolymer-sulfydryl group, polyethylene glycol and polyethylene glycol diacrylate. According to the scheme, the carrier material entrapped with the exosome has a dual targeting effect, so that the exosome or the exosome loaded with the medicine can accurately reach the ulceration position of the colonic mucosa, and accurate treatment is achieved; and the exosome is administrated in an oral dissolution manner, so that a patient can take the exosome with high compliance.

The application of mussel polysaccharide in preparation of a medicine for regulating the intestine-liver axis to treat alcoholic liver injury belongs to the technical field of natural products and biological medicine. The method takes mussel polysaccharide as an active ingredient, and divides experimental mice into a normal control group, an alcoholic liver injury model group, a positive control group and mussel polysaccharide low-, medium- and high-dose groups (60, 120 and 180 mg / kg / day), and continuously intervenes for 4 weeks. The results show that the mussel polysaccharide can significantly reduce liver function indexes such as ALT and AST, improve TC, TG, LDL-C, HDL-C related blood lipid disorders, protect the colon mucosal barrier, regulate the intestine-liver axis homeostasis, effectively reduce alcohol-induced liver fatty degeneration, inflammatory infiltration and oxidative stress injury, and the effect shows obvious dose dependence. The mussel polysaccharide is safe, non-toxic, economical in source, simple in intervention method and strong in repeatability, and provides a new way for the development of functional food and liver protection products for preventing and treating alcoholic liver injury.

This invention belongs to the field of bacterial agent preparation and biomedical technology, specifically relating to a strain of *Lactobacillus reuteri*, a bacterial agent, and its application in treating ulcerative colitis. This invention isolated a strain of *Lactobacillus reuteri*, named PFL-2501, and preserved it biologically. The *Lactobacillus reuteri* PFL-2501 exhibits strong gastrointestinal tolerance and high safety, with no hemolytic properties. It can inhibit harmful pathogenic bacteria in the intestine, regulate immune balance, reduce the content of pro-inflammatory factors in colonic tissue, decrease peroxidase activity, increase the level of anti-inflammatory factors, and improve the expression of intestinal tight junction proteins. The results of the examples show that *Lactobacillus reuteri* PFL-2501 and its bacterial agent can reduce weight loss in ulcerative colitis model mice, reduce the disease activity index, prolong colon length, protect the integrity of the colonic mucosa, and reduce inflammatory damage, thereby achieving a significant effect in alleviating ulcerative colitis.

The invention relates to the technical field of enema tubes, and discloses a colon cavity indwelling enema tube which comprises an enema catheter, the bottom of the enema catheter is fixedly connected with a hollow ball, output holes are evenly formed in the outer wall of the hollow ball, and a threaded groove is formed in the top of the enema catheter. The top of the enema catheter is provided with a guide assembly and a fixed sealing assembly, the guide assembly comprises a first end cap, the inner wall of the first end cap is in threaded connection with the interior of the threaded groove, the inner wall of the first end cap is fixedly connected with a guide wire, and the outer wall of the guide wire is arranged in the enema catheter. Accurate guide is provided for insertion of the enema catheter through the guide assembly, the hollow ball serves as a liquid output end and an insertion guide head, the risk that colonic mucosa is scratched in the insertion process is reduced, the leakage and pollution risks possibly occurring in the transfer process are avoided through the fixing and sealing assembly, and the flexible requirements of different infusion scenes are met.

This invention discloses a probiotic composite hydrogel with colonic mucosal targeting function, its preparation method, and its applications. The hydrogel uses thiolated sodium alginate and catechin-modified chitosan as a matrix, constructing a dual network structure through calcium ion-mediated ionic crosslinking and covalent crosslinking to encapsulate Bifidobacterium bifidum Z29-2. The hydrogel exhibits excellent mucosal adhesion and intestinal retention capacity, demonstrating good probiotic protection and sustained-release characteristics in simulated gastrointestinal fluid. The microspheres with 2.5% calcium ion crosslinking exhibit regular morphology and dense structure, significantly prolonging intestinal retention time. The composite hydrogel constructed in this invention combines protective, targeting, and sustained-release functions, can regulate mucin glycosylation, and enhance the intestinal barrier, showing promising application prospects in the field of intestinal microecological therapy.

Familial adenomatous polyposis (FAP) patients harbor mutations in the APC gene and will develop adenoma and early colorectal cancer. Taking biopsies from non-adenomatous (NA) and adenomatous (A) colonic mucosa of FAP patients, we investigated the early events associated with FAP using the intestinal organoid model. In addition to their high proliferative capacity, NA- and A-organoids were characterized by cysts and cysts with buds, respectively, suggesting abnormal maturation. A-organoids were enriched in the stem cell marker LGR5 and dependent on EGF and TGFβ for their growth. Downstream of EGFR, AKT, β-catenin and YAP were found to be activated in A-organoids. While the p110β isoform of PI3K was predominant in A-organoids and essential for their growth, p110α was associated with the immature state of NA-organoids. Accordingly, the present invention relates to a method of treating Familial Adenomatous Polyposis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a PI3K inhibitor.

The invention discloses a preparation method of colon powder for external use, and relates to the technical field of medicine preparation. The colon powder for external use is prepared from the following raw materials in parts by weight: 15 to 25 parts of radix astragali seu hedysari, 10 to 20 parts of radix pulsatillae, 8 to 18 parts of radix astragali seu hedysari, 6 to 16 parts of radix arnebiae seu lithospermi and 3 to 8 parts of auxiliary materials. The preparation method comprises the steps of raw material pretreatment, extraction, drying, mixing and sterilization. The raw materials also comprise the following components in parts by weight: 5-15 parts of purslane and 4-12 parts of cortex fraxini, and the weight ratio of the purslane to the cortex fraxini is 1: (0.8-1.2). According to the present invention, the radix astragali seu hedysari, the Chinese pulsatilla root, the radix astragali seu hedysari and the laver are adopted as the raw materials, the radix astragali seu hedysari has effects of spleen strengthening and qi supplementing, the Chinese pulsatilla root has effects of heat clearing and detoxification, the radix astragali seu hedysari has effects of immunity enhancing, and the radix arnebiae seu lithospermi has effects of blood cooling and blood activating so as to achieve multiple effects of inflammation resistance, colonic the treatment of ulcerative colitis and other diseases is remarkably improved, and the problems that an existing formula is single and the curative effect is limited are solved.

The invention belongs to the field of medicines, and particularly relates to application of Chinese torreya exosome nano-vesicles in preparation of medicines for treating or improving ulcerative colitis. The invention discloses a traditional medicine which discovers that XFEV not only can obviously reduce proinflammatory factors TNF-alpha and IL-6 and improve an anti-inflammatory factor IL-10, but also can repair a colonic mucosa crypt structure and enhance an intestinal barrier function, and is inferred to indirectly resist inflammation by regulating intestinal flora and is different from a single-mechanism traditional medicine. A plant exosome preparation process is optimized, uniform particles are obtained by combining differential centrifugation with sucrose gradient purification, the curative effect of XFEV delivered by an embedding method is proved to be remarkably superior to that of simple mixing, the targeting and protective advantages of the exosome as a natural carrier are highlighted, and a low-toxicity and high-efficiency new strategy is provided for UC treatment.

The application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis belongs to the field of biomedical technology. This invention addresses the limitations of existing treatments for inflammatory bowel disease (IBD), which suffer from limited efficacy, significant side effects, and difficulty in targeting and repairing the intestinal immune barrier. It provides the application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis. This recombinant ultra-high molecular weight hyaluronic acid can activate the intestinal IgA-producing immune network, regulate inflammation-related genes, and repair the physical and immune barriers of the colonic mucosa, thus exhibiting a superior protective effect against colitis compared to conventional hyaluronic acid, providing a new candidate drug for the treatment of IBD.

The invention discloses an application of herba siegesbeckiae aldehyde lactone in preparation of a medicine for treating colitis. The invention provides a novel application of an active ingredient of the traditional Chinese medicine herba siegesbeckiae in resisting colitis, and finds that the herba siegesbeckiae can relieve clinical symptoms of model animals and improve the condition of shortening of colon, has the functions of inhibiting inflammation of colonic mucosa and repairing intestinal barrier, ensures the structural form integrity of colon tissues, reduces inflammatory cell infiltration, and has the functions of resisting colitis. The pharmaceutical composition has the treatment effect equivalent to that of a positive drug sulfasalazine, also has in-vivo safety, and can reduce the content of inflammatory factors IL-6 and TNF-alpha in serum, reduce systemic inflammation and inhibit the development process of UC diseases. The invention lays a foundation for developing more new medicines for treating colitis, and provides a method and means.

The present application relates to the technical field of pharmaceutical compositions, and specifically discloses a phytosphingosine pharmaceutical composition, which comprises an active ingredient and a pharmaceutically acceptable carrier, wherein the active ingredient is phytosphingosine or a pharmaceutically acceptable salt, ester, derivative or prodrug thereof; and the pharmaceutical composition is a colon-targeted drug preparation, an oral enteric-coated preparation or a rectal drug preparation. The present application realizes direct protection of the colon epithelium and breaks through the action limitation of the existing treatment scheme. Phytosphingosine can maintain the integrity of the colon epithelial structure, improve the survival and proliferation of the colon epithelial cells and provide a basis for the repair of the damaged mucosa under the stimulation of inflammation; meanwhile, phytosphingosine can effectively regulate the expression and normal membrane positioning of the tight junction protein of the colon mucosa, repair the damaged intestinal epithelial barrier structure and reduce the intestinal mucosal permeability, thereby breaking the vicious cycle of epithelial damage-inflammation amplification in the pathogenesis of ulcerative colitis from the root.

The invention provides pogostemon cablin homogeneous polysaccharide PC-B-1 as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides pogostemon cablin homogeneous polysaccharide PC-B-1 and application thereof in preparation of a medicine for treating ulcerative colitis. A DSS-induced mouse ulcerative colitis model proves that PC-B-1 can significantly improve disease symptoms, including inhibition of weight loss, relieving of colon shortening and regulation of immune organ indexes. Histopathologic analysis (hematoxylin-eosin staining and alsine blue-periodate Schiff's staining) further shows that the PC-B-1 can effectively relieve inflammatory infiltration of the colonic mucosa and promote repair of goblet cells and mucus. The polysaccharide PC-B-1 with a novel structure is separated and identified from pogostemon cablin, and it is proved that the polysaccharide PC-B-1 has remarkable anti-inflammatory and intestinal mucosa protection activity and is expected to be developed into drugs for treating ulcerative colitis.

The application relates to the technical field of medical data processing, in particular to a Crohn's disease prediction method based on metabolism-immunity, which comprises a collection module, a peripheral blood and a colon mucosa biopsy sample of a subject are collected to obtain data; a prediction module, a Treg cell function index is calculated according to the data, a fatty acid oxidation pathway activation index is calculated; a Crohn's risk index is calculated and a result is output; the application takes an ALA-CPT1A / CD36-FAO-Treg cell function regulation axis as a core, quantitatively couples alpha-linolenic acid concentration, expression of a core molecule of an FAO pathway, a Treg cell function comprehensive index and a clinical correction factor, and sequentially constructs: a Treg cell function comprehensive index reflecting an immune core state; an FAO pathway synergistic activation index reflecting a regulation effect of metabolism on immunity; and prediction is realized in combination with the Treg cell function comprehensive index, the FAO index and clinical correction.

The invention discloses an application of recombinant lactoferrin in preparation of a product for preventing and treating intestinal injury caused by zearalenone. The recombinant lactoferrin is used for preventing and treating the intestinal injury caused by zearalenone, the body weight can be increased, the organ index can be recovered, the serum LPS level can be reduced, the colonic mucosa structure can be repaired, the colon tissue inflammation can be relieved, the number of goblet cells, epithelial cells and fibroblasts can be increased, and then the intestinal injury can be effectively relieved. Besides, according to colonic tissue single-cell transcriptome data of a recombinant lactoferrin treatment group, the action mechanism of the recombinant lactoferrin on the zearalenone-induced enterotoxicity is clarified, and a sufficient technical basis is provided for fully excavating the efficacy of the recombinant lactoferrin and preventing and treating the zearalenone-induced enterotoxicity.

This application discloses an information-based planning and evaluation system for the treatment of active ulcerative colitis, belonging to the field of planning and evaluation technology. By analyzing the state data of food and drugs after they pass through the digestive tract, and calculating sharpness and residue load, it quantifies the potential mechanical stimulation or burden that different foods and drugs may cause to the fragile and damaged colonic mucosa. It provides a more sensitive and accurate quantitative tool by automatically extracting microscopic feature data from endoscopic images. In addition to predicting drug efficacy, it also predicts mucosal healing trends under specific food patterns. Regarding drug recommendations, it obtains a drug recommendation list through weighted integration using machine learning models and the aforementioned prediction results. For dietary advice, it combines association rule mining and Bayesian networks to obtain specific food pattern suggestions, improving the targeting and patient suitability of dietary management, and enhancing the transparency and safety of clinical decision-making.

The invention belongs to the technical field of biological medicines, and relates to application of exogenous mitochondria in preparation of a medicine for treating colitis, and the exogenous mitochondria is derived from mammary epithelial cells. The exogenous mitochondria derived from mammary epithelial cells is used for treating young individual colitis for the first time, and the symptoms including inhibition of weight loss, improvement of diarrhea and hemafecia, repair of colonic mucosal lesion (such as crypt structure damage and inflammatory cell infiltration) and / or reduction of disease activity index (DAI score) can be remarkably relieved; the problems that in the prior art, mitochondria sources are limited, oral stability is poor, and the curative effect verification of a young model is insufficient are solved, and a new strategy is provided for colitis treatment.